These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1003 related items for PubMed ID: 26205801

  • 21. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A.
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [Abstract] [Full Text] [Related]

  • 23. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
    Arandi N, Haghpanah S, Safaei S, Zahedi Z, Ashrafi A, Eatemadfar P, Zarei T, Radwan AH, Taher AT, Karimi M.
    Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
    [Abstract] [Full Text] [Related]

  • 24. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 25. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Apr; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 26. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P, Meloni A, Pistoia L, Gamberini MR, Cuccia L, Allò M, Putti MC, Spasiano A, Rosso R, Cecinati V, Righi R, Renne S, Peritore G, Vallone A, Positano V, Quaia E, Cademartiri F, Pepe A.
    Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR, Delhikumar CG, Ram Kumar G.
    Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India.
    Parakh N, Chandra J, Sharma S, Dhingra B, Jain R, Mahto D.
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):209-213. PubMed ID: 28221264
    [Abstract] [Full Text] [Related]

  • 29. Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
    Forni GL, Podestà M, Musso M, Piaggio G, Musallam KM, Balocco M, Pozzi S, Rosa A, Frassoni F.
    Haematologica; 2013 Apr; 98(4):555-9. PubMed ID: 23242593
    [Abstract] [Full Text] [Related]

  • 30. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Apr; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 31. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
    Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E.
    Blood Cells Mol Dis; 2013 Feb; 50(2):99-104. PubMed ID: 23151373
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
    Premawardhena A, Perera C, Wijethilaka MN, Wanasinghe SK, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S.
    BMJ Open; 2024 Feb 08; 14(2):e077342. PubMed ID: 38331857
    [Abstract] [Full Text] [Related]

  • 34. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A, Kontoghiorghes GJ.
    Front Biosci (Landmark Ed); 2018 Jan 01; 23(6):1082-1098. PubMed ID: 28930590
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Jan 01; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 36. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Jan 01; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 37. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, Terlizzi F, Guitarrini MR, Monti S, Maffei L, Losardo A, Pasin M, Toscano V.
    Ann Hematol; 2016 Apr 01; 95(5):757-63. PubMed ID: 26957357
    [Abstract] [Full Text] [Related]

  • 38. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N, Ali S, Butt MA.
    J Ayub Med Coll Abbottabad; 2014 Apr 01; 26(3):297-300. PubMed ID: 25671931
    [Abstract] [Full Text] [Related]

  • 39. Current status of iron overload and chelation with deferasirox.
    Choudhry VP, Naithani R.
    Indian J Pediatr; 2007 Aug 01; 74(8):759-64. PubMed ID: 17785900
    [Abstract] [Full Text] [Related]

  • 40. Combined therapy with deferiprone and desferrioxamine.
    Wonke B, Wright C, Hoffbrand AV.
    Br J Haematol; 1998 Nov 01; 103(2):361-4. PubMed ID: 9827905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.